Kyntra Bio, Inc. share price logo

Kyntra Bio, Inc. Share Price

NASDAQ: KYNB

Small Cap

$7.22

+0.03

(+0.42%)

as on

Kyntra Bio, Inc. Stock Performance

as on April 18, 2026 at 6:49 am IST

  • Day's Low

    Day's High

    $7.20
    $7.30
    downward going graph

    0.28%

    Downside

    1.11%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Kyntra Bio, Inc. share price movements today

Previous Close
$7.19
Open
$7.22
Volume
54.0K
Day's Low - High
$7.20 - $7.30

Kyntra Bio, Inc. Historical Returns

1 Month Return
-2.44 %
3 Month Return
-21.33 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Kyntra Bio, Inc. Stock Fundamentals & Key Indicators

Check Kyntra Bio, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$28.8M

EPS (TTM)

-13.54

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Kyntra Bio, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyntra Bio, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Kyntra Bio, Inc. image
Kyntra Bio, Inc.
NA$28.8MNANA2848.63%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B130.51%136.818.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.8B98.57%28.4232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$36.8BNA129.845.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B48.43%17.9831.41%

Kyntra Bio, Inc. Stock’s Investor Sentiment and Interest

Search interest for Kyntra Bio, Inc. Stock has decreased by -59% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-59% versus previous 30 day period

Kyntra Bio, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
40
27
25
0
46
-123
2
1
1
1
Gross Profit
35
21
-32
-31
41
-102
2
1
1
0
Operating Income
-63
-54
-49
-46
-16
-91
-14
-12
-5
-13
EBITDA
-56
-49
-48
-45
-12
-91
-14
-11
-10
-9
Interest Expense
5
5
2
1
4
2
2
2
2
-2
Depreciation
-
-
-
-
0
0
0
0
0
0
Income Before Tax
-63
-56
-49
-47
-17
-87
-16
-13
-13
-14
Income Tax Expense
0
0
0
0
0
0
0
0
-
0
Net Income
-63
-56
-32
-15
-17
17
4
-7
200
-14
Net Profit Margin
-158.51%
-207.21%
-129.84%
-1557.52%
-36.87%
-14.59%
169.37%
-564.02%
18646.47%
-1112.68%

Kyntra Bio, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
179
125
212
256
176
235
140
46
29
6
Gross Profit
-7
-70
-22
255
167
-213
120
42
14
5
Operating Income
-53
-122
-86
-89
-191
-288
-301
-322
-150
-45
EBITDA
-44
-104
-68
-52
-164
-333
-282
-305
-142
-45
Interest Expense
10
9
10
2
2
1
1
8
8
-8
Depreciation
-
-
-
-
-
14
10
9
2
0
Income Before Tax
-61
-125
-86
-76
-188
-289
-293
-323
-153
-58
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-61
-126
-86
-76
-189
-290
-293
-284
-47
183
Net Profit Margin
-34.35%
-100.43%
-40.58%
-30.00%
-107.36%
-123.25%
-208.66%
-607.29%
-160.63%
2848.63%

Kyntra Bio, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-56
-32
-15
-17
17
4
-7
-13
-14
Operating Cash Flow
-18
-59
-39
-8
-30
2
12
-1
-18
Investing Cash Flow
10
51
72
0
1
0
0
87
-51
Financing Cash Flow
0
0
0
0
0
0
0
-85
0
Change in Cash
-7
-7
34
-9
-28
4
13
94
-70

Kyntra Bio, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-120
-86
-76
-189
-290
-293
-284
-47
183
Operating Cash Flow
-66
-76
-78
81
-82
-145
-315
-137
-4
Investing Cash Flow
69
-522
120
452
-426
89
153
125
35
Financing Cash Flow
496
13
-4
13
0
46
122
0
-86
Change in Cash
499
-584
37
552
-507
-15
-42
-11
-54

Insights on Kyntra Bio, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.07M → 1.27M (in $), with an average increase of 15.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 21.1% return, outperforming this stock by 119.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 38.8% return, outperforming this stock by 38.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 200.63M → -14.22M (in $), with an average decrease of 107.1% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, KYNB stock has moved down by -98.6%

About Kyntra Bio, Inc.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
OrganisationKyntra Bio, Inc.
Headquarters350 Bay Street, San Francisco, CA, United States, 94133
IndustryBiotechnology
CEOMr. Thane Wettig
E-voting on sharesClick here to vote

Key Management of Kyntra Bio, Inc.

Name

Title

Mr. Thane Wettig

CEO & Director

Mr. David DeLucia

Senior VP & CFO

Mr. John Alden

Corporate Secretary & General Counsel

Ms. Gaia Vasiliver-Shamis

Director of IR & Communications - LifeSci Advisors

FAQs

What is Kyntra Bio, Inc. share price today?

Kyntra Bio, Inc. share price today is $7.22 as on at the close of the market. Kyntra Bio, Inc. share today touched a day high of $7.3 and a low of $7.2.

What is the 52 week high and 52 week low for Kyntra Bio, Inc. share?

Kyntra Bio, Inc. share touched a 52 week high of $ on and a 52 week low of $ on . Kyntra Bio, Inc. stock price today i.e. is closed at $7.22,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Kyntra Bio, Inc.'s market capitalisation today?

Kyntra Bio, Inc. market capitalisation is $0.00T as on .

How to invest in Kyntra Bio, Inc. Stock (KYNB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kyntra Bio, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyntra Bio, Inc. Shares that will get you 0.2078 shares as per Kyntra Bio, Inc. share price of $7.22 per share as on April 18, 2026 at 1:19 am IST.

What is the minimum amount required to buy Kyntra Bio, Inc. Stock (KYNB) from India?

Indian investors can start investing in Kyntra Bio, Inc. (KYNB) shares with as little as ₹92.768 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹927.68 in Kyntra Bio, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Kyntra Bio, Inc. share’s latest price of $7.22 as on April 18, 2026 at 1:19 am IST, you will get 1.3850 shares of Kyntra Bio, Inc.. Learn more about fractional shares .